Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Show Comparable Functionality to Their Autologous Origin.

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Oncology

Background:

• Radiotherapy for head and neck squamous cell carcinoma causes damage to surrounding healthy tissues.
• Tissue regeneration and wound healing rely on stem cell survival and regenerative capacities.
• Mesenchymal stem cells (MSCs) show therapeutic potential in regenerative medicine due to immunomodulatory and differentiation properties, but their generation is challenging.

Purpose of the Study:

• To produce highly homogeneous induced pluripotent stem cell-derived mesenchymal stem cells (iP-MSCs) in an autologous manner.
• To isolate human mucosa mesenchymal stem cells (mMSCs) from the upper respiratory tract for reprogramming.
• To evaluate the therapeutic potential and characteristics of autologous iP-MSCs.

Main Methods:

• Reprogramming of mMSCs into induced pluripotent stem cells (iPSCs) using non-integrative chromosomal technologies.
• Differentiation of iPSCs into iP-MSCs.
• Characterization of mMSCs and iP-MSCs, including morphology, clonogenic potential, differentiation, surface phenotype, and immunosuppressive capacity.

Main Results:

• mMSCs were successfully reprogrammed into iPSCs and subsequently differentiated into iP-MSCs.
• mMSCs and iP-MSCs exhibited similar cell characteristics, including morphology, clonogenic potential, differentiation capabilities, and surface markers.
• iP-MSCs demonstrated comparable immunosuppressive capacity to mMSCs, including cytokine secretion and T cell inhibition.

Conclusions:

• Autologous iP-MSC generation from mMSCs is feasible and yields cells with similar characteristics and therapeutic potential.
• This approach may offer a novel personalized treatment option for regenerative medicine, potentially mitigating radiotherapy side effects.
• Further research into autologous iP-MSCs could advance personalized regenerative strategies in oncology and beyond.